Evidence-based medicine: Facts and controversies

Clinics in Dermatology

Volumn 28, Issue 5, 2010, Pages 553-557

  Darlenski, Razvigor Borislavov ^a   Neykov, Neyko Valentinov ^a   Vlahov, Vitan Dakov ^a   Tsankov, Nikolaï Konstantinov ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CALCINEURIN INHIBITOR; CALCIPOTRIOL; GLUCOCORTICOID; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; SILDENAFIL; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFLICT OF INTEREST; EVIDENCE BASED MEDICINE; HUMAN; INDIVIDUALIZATION; MALARIA; MEDICAL RESEARCH; OFF LABEL DRUG USE; POPULATION RESEARCH; PRIORITY JOURNAL; PSORIASIS; PUBLISHING; RARE DISEASE; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; SCLERODERMA; SEXUALLY TRANSMITTED DISEASE; SKIN DISEASE; TREATMENT RESPONSE;

CONFLICT OF INTEREST; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; SKIN DISEASES;

EID: 77955963222     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2010.03.015     Document Type: Article

References (33)

1. Namora F. Deuses e Demônios da Medicina Lisboa: Livros do Brasil Limitada 1952.
2. Black's Medical Dictionary 2005, 253. A&C Black Publishers Limited, London. 41st ed.
3. Sackett D.L., Rosenberg W.M., Gray J.A., Haynes R.B., Richardson W.S. Evidence based medicine: what it is and what it isn't. BMJ 1996, 312:71-72.
4. Guyatt G. Evidence-based medicine. ACP J Club (Ann Intern Med) 1991, 14:A-16.
5. Eddy DM. Practice policies: where do they come from? JAMA 1990;263:1265, 9, 72 passim.
6. Manchikanti L., Hirsch J.A., Smith H.S. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 2: randomized controlled trials. Pain Physician 2008, 11:717-773.
7. Milne R., Chambers L. Assessing the scientific quality of review articles. J Epidemiol Community Health 1993, 47:169-170.
8. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 1992, 268:2420-2425.
9. Leonard T., Delamere F., Murrell D. Evidence-based dermatology 2003, 24-32. The Cochrane Skin Group, BMJ Publishing Group, London. 1st ed.
10. Feinstein A.R. What kind of basic science for clinical medicine?. N Engl J Med 1970, 283:847-852.
11. Campbell E.J. The diagnosing mind. Lancet 1987, 1:849-851.
12. McColl A., Smith H., White P., Field J. General practitioner's perceptions of the route to evidence based medicine: a questionnaire survey. BMJ 1998, 316:361-365.
13. De Vito C., Nobile C.G., Furnari G., et al. Physicians' knowledge, attitudes and professional use of RCTs and meta-analyses: a cross-sectional survey. Eur J Public Health 2009, 19:297-302.
14. Naldi L. The field and its boundaries. Evidence-based dermatology 2003, 3-8. BMJ Publishing Group, London. 1st ed.
15. Kravitz R.L., Duan N., Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 2004, 82:661-687.
16. Stratigos A.J., Katsambas A.D. Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients. Am J Clin Dermatol 2004, 5:161-168.
17. Chaudhry H.J., McDermott B. Recognizing and improving patient nonadherence to statin therapy. Curr Atheroscler Rep 2008, 10:19-24.
18. Kagan A.R., Burchette R.J., Iganej S. The case for case reports: avoiding statistical seduction. Am J Clin Oncol 2006, 29:325-327.
19. Schaefer I., Rustenbach S.J., Zimmer L., Augustin M. Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 2008, 217:169-172.
20. Verhoeven E.W., Kraaimaat F.W., van Weel C., et al. Skin diseases in family medicine: prevalence and health care use. Ann Fam Med 2008, 6:349-354.
21. Wahlgren C.F., Edelbring S., Fors U., Hindbeck H., Stahle M. Evaluation of an interactive case simulation system in dermatology and venereology for medical students. BMC Med Educ 2006, 6:40.
22. Blondon K., Desmeules J., Vogt-Ferrier N., Besson M., Kondo-Oestreicher M., Dayer P. Off-label prescribing. Rev Med Suisse 2008, 4:1661-1665.
23. Pearce D.J., Camacho F., Balkrishnan R., Fleischer A.B., Feldman S.R. Trends in on and off-label calcipotriene use. J Dermatolog Treat 2006, 17:308-313.
24. Rallis E., Korfitis C., Gregoriou S., Rigopoulos D. Assigning new roles to topical tacrolimus. Expert Opin Investig Drugs 2007, 16:1267-1276.
25. Pura M., Kreze A. From the history of endocrinology: reminiscence of the discovery of adrenocortical hormones. Cas Lek Cesk 2005, 144:648-650. [discussion 50-1].
26. Graves J.E., Nunley K., Heffernan M.P. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol 2007, 56:e55-e79.
27. Antonelli M., Mercurio G. Reporting, access, and transparency: better infrastructure of clinical trials. Crit Care Med 2009, 37(1 suppl):S178-S183.
28. Abaid L.N., Grimes D.A., Schulz K.F. Reducing publication bias through trial registration. Obstet Gynecol 2007, 109:1434-1437.
29. Nunn R. Evidence-based medicine and limits to the literature search. J Eval Clin Pract 2008, 14:672-678.
30. Tsankov N., Angelova I., Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000, 1:159-165.
31. Kuflik E.G. Effect of antimalarial drugs on psoriasis. Cutis 1980, 26:153-155.
32. Vlahov V. Personalized pharmacotherapy: principles and practice. Presented at: Fourth International Symposium Clinical Pharmacology and Therapeutics; Sofia, Bulgaria 2007, 15.
33. Pirmohamed M. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J 2006, 8:E20-E26.